Novartis CEO Narasimhan says AI could cut drug development from 12 years to eight
Narasimhan, who also sits on Anthropic's board, told Bloomberg that Novartis already uses AI in clinical trials, data analysis and drug candidate discovery.
What happened
Novartis is a large drug company. Its CEO, Vasant Narasimhan, says artificial intelligence could shorten the time it takes to create a new medicine from 12 years to eight. He says it could also improve the odds that a new medicine reaches the market.
Why it matters to you
Faster development could mean new treatments reach patients sooner. It could also lower the cost of building them.
The takeaway
A drug company CEO says AI could take four years off drug development.
What it means for you
Clinical trial speed, data analysis and candidate identification are the areas where Novartis says it already uses AI.
A CEO of a major drugmaker is putting a figure of four years on potential AI savings in development time.
Novartis's CEO links AI to development timelines and success odds, and Bloomberg reports he also discussed the company's growth outlook.